

LIFE SAVING DRUGS PROGRAM EXPERT PANEL
13th MEETING: 14 October 2022

AGENDA

1. Standing business

- 1.1 Welcome, apologies and potential or actual Conflicts of Interest
- 1.2 Update on actions from previous meetings
- 1.3 Correspondence
- 1.4 Report from the Secretariat

2 Reviews of existing LSDP medicines

- 2.1 Review of Elosulfase alfa (Vimizim®)

3 Applications for new LSDP medicines

- 3.1 Sebelipase alfa (Kanuma®) – for the treatment of infantile onset lysosomal acid lipase deficiency (L-LAD)

4 Other business